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Abstract
Background: The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate
cancer patients with or without baseline opioid use.
Objective: To assess the efﬁcacy and safety of radium-223 dichloride (radium-223) versus
placebo in ALSYMPCA patients by baseline opioid use.
Design, setting, and participants: Nine hundred and twenty one patients enrolled at 136 cen-
ters globally.
Intervention: Radium-223 (50 kBq/kg, intravenous injection) every 4 wk for six cycles or
matching placebo, each plus best standard of care.
Outcome measurements and statistical analysis: Primary endpoint (overall survival [OS]),
main secondary efﬁcacy endpoints, and safety were evaluated by baseline opioid use.
Additional analyses included time to ﬁrst opioid use, time to ﬁrst external beam radiation
therapy for bone pain, and safety of concomitant external beam radiation therapy.
Results and limitations: At baseline, 408 (44%) patients had no pain and no analgesic use or
mild pain with nonopioid therapy (World Health Organization ladder pain score 0–1 [non-
opioid subgroup]), and 513 (56%) had moderate pain with occasional opioids or severe pain
with regular daily opioids (World Health Organization ladder pain score 2–3 [opioid sub-
group]). Radium-223 signiﬁcantly prolonged OS versus placebo in nonopioid (hazard ratio
[HR] = 0.70; 95% conﬁdence interval [CI]: 0.52–0.93; p = 0.013) and opioid (HR = 0.68; 95% CI:
0.54–0.86; p = 0.001) subgroups, and signiﬁcantly reduced risk of symptomatic skeletal events
versus placebo, regardless of baseline opioid use (nonopioid subgroup: HR = 0.56, 95% CI: 0.39–
0.82, p = 0.002; opioid subgroup: HR = 0.72, 95% CI: 0.53–0.98, p = 0.038). Time to ﬁrst opioid
use for bone painwas signiﬁcantly delayedwith radium-223 versus placebo (HR = 0.62, 95% CI:
0.46–0.85, p = 0.002). Adverse event incidences were similar between opioid subgroups.
Conclusions: Radium-223 versus placebo signiﬁcantly prolonged OS and reduced symptom-
atic skeletal event risk with a favorable safety proﬁle in castration-resistant prostate cancer
patients with symptomatic bone metastases, regardless of baseline opioid use.
Patient summary: In this ALSYMPCA opioid subgroup analysis, baseline symptom levels did
not appear to impact radium-223 dichloride efﬁcacy or safety.
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Radium-223 dichloride (radium-223), a first-in-class alpha-
emitting radiopharmaceutical [1–3], has demonstrated
survival benefits for patients with symptomatic bone
metastases from castration-resistant prostate cancer
(CRPC). In the randomized phase 3 ALSYMPCA study,
radium-223 plus best standard of care (BSoC) versus
placebo plus BSoC prolonged median overall survival (OS)
by 3.6mo (hazard ratio [HR] = 0.70; 95% confidence interval
[CI]: 0.58–0.83; p < 0.001; median 14.9 mo vs 11.3 mo,
respectively) and prolonged median time to first symptom-
atic skeletal event (SSE) by 5.8 mo (HR = 0.66; 95% CI: 0.52–
0.83; p < 0.001; median 15.6 mo vs 9.8 mo, respectively) in
patients with CRPC and symptomatic bone metastases
[4,5]. Additionally, radium-223 had a favorable safety
profile with a low myelosuppression rate [4]. ALSYMPCA
results led to radium-223 approval for the treatment of
CRPC patients with symptomatic bone metastases and no
known visceral metastatic disease [6].
Unlike the phase 2 radium-223 dose-response pain study
[7], ALSYMPCA was not designed to evaluate the effect of
radium-223 on pain; the primary endpoint was OS, and all
patients received BSoC during the study, including treat-
ments to manage pain (eg, external beam radiation therapy
[EBRT], analgesics) [4]. ALSYMPCA eligibility required
having symptomatic disease, broadly defined to include
patients with regular use of analgesic medication (non-
opioid or opioid) or pain-free patients who received EBRT
for cancer-related bone pain in the 12 wk before randomi-
zation [4]. At baseline, 44% of radium-223 and 45% of
placebo patients had no pain or had mild pain effectively
managed without need for opioids; the remaining patients
(56% radium-223 and 55% placebo) required opioids at
study entry [4].
The efficacy and favorable safety of radium-223 was
observed in the overall ALSYMPCA population that included
patients both with and without baseline opioid use. The
question arises of whether the radium-223 survival
advantage depended on patients’ baseline symptom severi-
ty. In other words, would patients with no or minimal
symptoms benefit from radium-223 as much as those with
symptoms? To address this question, we assessed the
efficacy and safety of radium-223 versus placebo in
ALSYMPCA patients who did not require opioid therapy
at baseline (ie, minimally symptomatic disease) versus
those receiving opioids at baseline (ie, symptomatic
disease). Additional analyses assessed the impact of
radium-223 on delaying the need for opioids or EBRT for
bone painmanagement and the safety of concomitant EBRT.
2. Patients and methods
2.1. Patients and study design
ALSYMPCAwas a phase 3, randomized, double-blind, placebo-controlled
study conducted at 136 centers in 19 countries to compare the efﬁcacy
and safety of radium-223 plus BSoC versus placebo plus BSoC in CRPC
patients with symptomatic bone metastases. Patient eligibility criteriawere previously reported [4,5,8]. Brieﬂy, eligible patients had histologi-
cally conﬁrmed, progressive CRPC, at least two bone metastases, no
known visceral metastases, and symptomatic disease deﬁned as regular
use of nonopioid analgesics or opioidmedication for cancer-related bone
pain (World Health Organization [WHO] ladder pain score  1) or EBRT
for cancer-related bone pain in the 12 wk prior to randomization.
Patients were randomized (2:1) to receive either six intravenous
injections of radium-223 50 kBq/kg (55 kBq/kg following the National
Institute of Standards and Technology update [9]) or matching placebo,
one injection every 4 wk. Patients were stratiﬁed by previous docetaxel
use (yes or no), baseline total alkaline phosphatase (tALP) serum level
(<220 U/l or 220 U/l), and bisphosphonate use at study entry (yes or
no). All patients received BSoC available at each center (Supplementary
Table 1). The planned follow-up was 3 yr from ﬁrst study-drug injection.
Review boards at all participating centers approved the study, and all
patients provided written informed consent. The study was registered
with ClinicalTrials.gov, number NCT00699751.
2.2. Procedures
Opioids were permitted prior to and during ALSYMPCA, but were not a
requirement for study entry. Investigators were free to manage bone
pain during the study by starting nonopioid analgesics, or adding EBRT or
opioids to pre-existing nonopioid analgesics as recommended by the
WHO guidelines [10]. EBRT could be administered at any time prior to
randomization or within 12 wk prior to randomization to fulﬁll the
eligibility requirement of symptomatic disease and was allowed during
the study as part of BSoC. Time to ﬁrst EBRT use for bone pain was
documented as a component of the secondary endpoint time to ﬁrst SSE.
2.3. Opioid subgroups and study assessments
This analysiswas designed to assess radium-223 efﬁcacy and safety in the
subgroupsofpatientswhohadorhadnot receivedopioidsatbaseline. Two
subgroups were deﬁned: the nonopioid subgroup included patients with
nopainandnoanalgesicuse (WHOladderpain score0)ormildpainandno
opioid use (WHO ladder pain score 1) at baseline; the opioid subgroup
included patients with moderate pain and occasional opioid use (WHO
ladder pain score 2) or severe pain and regular daily opioid use
(WHO ladder pain score 3) at baseline.
2.4. Outcomes
Patient outcomes by baseline opioid use and treatment group were
evaluated for the ALSYMPCA primary endpoint (OS), main secondary
efﬁcacy endpoints, and safety. OS was deﬁned as time from randomiza-
tion to date of death, regardless of cause. Main secondary efﬁcacy
endpoints were time to ﬁrst SSE (deﬁned as ﬁrst EBRT use to relieve bone
pain, or occurrence of new symptomatic pathologic bone fractures
[vertebral or nonvertebral], spinal cord compression, or tumor-related
orthopedic surgical intervention); time to prostate-speciﬁc antigen
(PSA)-level increase; time to tALP-level increase; conﬁrmed 30%
reduction in tALP response; and tALP normalization. The initial trial
report contains a complete description of these efﬁcacy and safety
endpoints [4].
2.5. Statistical analyses
Analyses of OS by opioid subgroup and time to ﬁrst EBRT use for bone
pain were speciﬁed in the protocol and included in the original planned
analysis. Subsequent, exploratory analyses included the main secondary
efﬁcacy endpoints by opioid subgroup, safety by opioid subgroup, time
to ﬁrst use of opioids, and safety with concomitant EBRT. All data were
prospectively collected.
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treat (ITT) population, including all randomized patients. Safety analyses
were based on the safety population, including all patients who received
at least one study-drug injection. A log-rank test was used to analyze OS
and main secondary efﬁcacy endpoints of time to ﬁrst SSE, time to tALP
increase, and time to PSA increase. HRs were estimated using the Cox
proportional hazards regression model. Both the log-rank test and the
Cox model were stratiﬁed by tALP, bisphosphonate use at study entry,
and prior docetaxel use. An unstratiﬁed Cox proportional hazards model
was used to test the treatment by opioid subgroup interaction. Median
values for time-to-event variables (OS, time to ﬁrst SSE, time to tALP
increase, time to PSA increase, time to ﬁrst opioid use, and time to ﬁrst
EBRT)were assessed using the Kaplan-Meiermethod and censored at the
last known alive date or patient assessment date, if an event had not
occurred at time of analysis or the patient was lost to follow-up. tALP
response and normalization were analyzed using a Cochran-Mantel-
Haenszel analysis adjusting for stratiﬁcation factors tALP, current
bisphosphonate use, and prior docetaxel use. Safety analyses were
descriptive.
Additional analyses evaluated the radium-223 effect on addition of
opioids or need for EBRT. Time to ﬁrst on-study opioid use was assessed
in patients not receiving opioids at baseline (ie, nonopioid subgroup).
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Fig. 1 – Consolidated Standards of Reporting Trials diagram.
radium-223 = radium-223 dichloride.
a Eighteen patients who were not being treated were withdrawn from the stud
group and five from the placebo group); an additional two patients received n
b One patient was randomly assigned to the placebo but received radium-223
intention-to-treat population (placebo group) and is included in the radium-2
c Patients who discontinued treatment but continued to participate through fo
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e Patients in the placebo group who received treatment with radium-223 after
discontinued treatment or withdrawn from the study.Time to ﬁrst EBRT use for bone pain was a component of the SSE main
secondary efﬁcacy endpoint and was assessed in the overall ALSYMPCA
ITT population. Adverse events (AEs) by concomitant EBRT were
analyzed in the ALSYMPCA safety population.
3. Results
3.1. Nonopioid and opioid subgroups
Of the 921 patients randomized in the ALSYMPCA ITT
population, 408 (44%) had no pain and no analgesic use
(WHO ladder pain score 0) or mild pain managed with
nonopioid therapy (WHO ladder pain score 1) at baseline
(nonopioid subgroup: radium-223, n = 269; placebo,
n = 139), and 513 (56%) had moderate pain with occasional
opioids (WHO ladder pain score 2) or severe pain with
regular daily opioids (WHO ladder pain score 3) at baseline
(opioid subgroup: radium-223, n = 345; placebo, n = 168;
Fig. 1). In the nonopioid subgroup, 12 of 269 (4%)
radium-223 patients and two of 139 (1%) placebo patients5 withdrawn early
before first study
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301 included in the safety populationb
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y before the first injection of the study drug (13 from the radium-223
o treatment and had missing dates of withdrawal.
at week 0; this patient is included as randomly assigned in the
23 group for the safety population.
llow-up were not regarded as withdrawn from the study; the study was
o the total number treated.
ving withdrawn early from the study; the study was ongoing at the time
reated.
the study was unblinded; these patients were not regarded as having
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inclusion criteria for symptomatic disease, having received
EBRT in the 12 wk prior to randomization.
3.2. Patient demographics and baseline characteristics
Demographics and baseline characteristics were generally
balanced between nonopioid and opioid subgroups and the
overall ALSYMPCA ITT population (Table 1). Compared with
radium-223 patients who required opioids, those in the
nonopioid subgroup appeared to have less advanced
disease, suggested by a greater proportion with tALP values
<220 U/l, lower median tALP and lactate dehydrogenase
values, better performance status, and less extensive
skeletal disease. Also, fewer had prior docetaxel therapy
and EBRT for pain in the 12 wk prior to randomization. A
similar trend was seen among placebo patients (Table 1).
Irrespective of treatment allocation, the survival duration
and time to first SSE were longer in minimally symptomatic
(ie, WHO ladder pain score 0–1/without opioid use) than in
more symptomatic patients (ie,WHO ladder pain score 2–3/
with opioid use).Table 1 – Patient demographics and baseline characteristics
Characteristicsa Nonopioid subgroup
Radium-223
n = 269
Place
n = 1
Age
Median (range), yr 72 (51–90) 73 (50–
Total alkaline phosphatase level, n (%)
<220 U/l 169 (63) 82 (59)
220 U/l 100 (37) 57 (41)
Current use of bisphosphonates, n (%)
Yes 105 (39) 57 (41)
No 164 (61) 82 (59)
Prior use of docetaxel, n (%)
Yes 139 (52) 73 (53)
No 130 (48) 66 (48)
ECOG performance status score, n (%)
0 99 (37) 44 (32)
1 151 (56) 84 (60)
2 18 (7) 11 (8)
WHO ladder for cancer pain, n (%)
0 (no pain; no opioid use) 12 (4) 2 (1)
1 (mild pain; no opioid use) 257 (96) 137 (99)
2 (moderate pain; occasional opioid use) 0 0
3 (severe pain; regular daily opioid use) 0 0
EBRT to bone 12 wk prior to randomization, n (%) 33 (12) 20 (14)
Extent of disease, n (%)
<6 metastases 56 (21) 19 (14)
6-20 metastases 120 (45) 67 (48)
>20 metastases or superscanb 91 (34) 53 (38)
Median biochemical values (range)c
Hemoglobin (g/dl) 13 (9–16) 13 (9–1
Albumin (g/l) 40 (26–53) 40 (24–
Total alkaline phosphatase (U/l) 164 (32–6431) 213 (29–
Lactate dehydrogenase (U/l) 280 (121–1969) 321 (138
Prostate-speciﬁc antigen (mg/l) 145 (4–5790) 165 (2–4
EBRT = external beam radiation therapy; ECOG = Eastern Cooperative Oncology
World Health Organization.
a Percentages may not sum to 100 due to rounding.
b Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the
c The normal biochemical ranges are as follows: hemoglobin, 13–17 g/dl; album
115–255 U/l; and prostate-speciﬁc antigen, 0–3.999 mg/l.3.3. Efficacy: survival
Radium-223 significantly prolonged OS, regardless of base-
line opioid use. Consistent OS benefits were seen with
radium-223 treatment versus placebo in nonopioid
(HR = 0.70; 95% CI: 0.52–0.93; p = 0.013; median 16.4 mo
vs12.8mo, respectively) andopioid (HR = 0.68; 95%CI: 0.54–
0.86; p = 0.001; median 13.9 mo vs 10.4 mo, respectively)
subgroups (Fig. 2, A and B). The treatment by opioid
subgroup interaction was not statistically significant
(p = 0.985), indicating that there is nodifference in treatment
effect between the opioid and nonopioid subgroups for OS.
3.4. Efficacy: SSE and other main secondary efficacy endpoints
Radium-223 treatment significantly reduced the risk of
SSEs compared with placebo, regardless of baseline opioid
use (nonopioid subgroup: HR = 0.56, 95% CI: 0.39–0.82,
p = 0.002; opioid subgroup: HR = 0.72, 95% CI: 0.53–0.98,
p = 0.038; (Fig. 2, C and D). Additionally, all main secondary
efficacy endpoints were met, regardless of baseline opioid
use (Table 2).Opioid subgroup ITT population
bo
39
Radium-223
n = 345
Placebo
n = 168
Radium-223
n = 614
Placebo
n = 307
89) 71 (49–88) 69 (44–94) 71 (49–90) 71 (44–94)
179 (52) 87 (52) 348 (57) 169 (55)
166 (48) 81 (48) 266 (43) 138 (45)
145 (42) 67 (40) 250 (41) 124 (40)
200 (58) 101 (60) 364 (59) 183 (60)
213 (62) 101 (60) 352 (57) 174 (57)
132 (38) 67 (40) 262 (43) 133 (43)
66 (19) 34 (20) 165 (27) 78 (25)
220 (64) 103 (61) 371 (60) 187 (61)
59 (17) 30 (18) 77 (13) 41 (13)
0 0 12 (2) 2 (1)
0 0 257 (42) 137 (45)
151 (44) 78 (46) 151 (25) 78 (25)
194 (56) 90 (54) 194 (32) 90 (29)
66 (19) 28 (17) 99 (16) 48 (16)
44 (13) 19 (11) 100 (16) 38 (12)
142 (41) 80 (48) 262 (43) 147 (48)
158 (46) 68 (40) 249 (41) 121 (39)
6) 12 (9–15) 12 (9–16) 12 (9–16) 12 (9–16)
50) 40 (24–52) 40 (23–49) 40 (24–53) 40 (23–50)
3225) 240 (40–2727) 235 (36–4805) 211 (32–6431) 223 (29–4805)
–3856) 342 (76–2171) 350 (132–2836) 315 (76–2171) 336 (132–3856)
850) 151 (4–6026) 173 (7–14500) 146 (4–6026) 173 (2–14500)
Group; ITT = intent-to-treat; radium-223 = radium-223 dichloride; WHO =
tracer without renal and background activity.
in, 36–45 g/l; total alkaline phosphatase, 35–105 U/l; lactate dehydrogenase,
[(Fig._2)TD$FIG]
Fig. 2 – Kaplan-Meier estimates of (A, B) overall survival and (C, D) time to first symptomatic skeletal event by baseline opioid use (intent-to-treat
population; N = 921); and (E) time to first opioid use in patients without baseline opioid use (nonopioid subgroup, n = 408).
CI = confidence interval; HR = hazard ratio; radium-223 = radium-223 dichloride; SSE = symptomatic skeletal event.
a Median time to first symptomatic skeletal event in the nonopioid subgroup was longer for placebo patients versus radium-223 patients (19.5 mo vs
17.1 mo, respectively), as few patients were left in the placebo group toward the end of the assessment period and the curves crossed before median
time to first symptomatic skeletal event was reached, thus the tail end of the curves were not reliably estimated. The 25th percentile was 8.3 mo for
radium-223 patients and 5.2 mo for placebo patients, indicating the treatment benefit of radium-223 during the early part of the study, when most
patients were evaluable. Hazard ratio is the most appropriate statistical parameter to best interpret the treatment difference over the entire observed
time frame.
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No clinically meaningful treatment differences in the
incidence of hematologic or nonhematologic AEs were
observed between nonopioid and opioid subgroups
(Table 3), despite the slightly higher AE incidence (all grades
and Grade 3/4) in the opioid subgroup for radium-223 and
placebo patients, which may reflect more advanced disease
in these patients. Although rare, Grades 3/4 neutropenia and
thrombocytopenia occurred more frequently in radium-223
patients versus placebo patients, regardless of opioid
subgroup (nonopioid subgroup: neutropenia in 2% vs 1%,
thrombocytopenia in 5% vs 1%; opioid subgroup: neutrope-
nia in 2% vs 1%, thrombocytopenia in 7% vs 2%; Table 3).
3.6. Radium-223 with concomitant opioids or EBRT for bone
pain management
As mentioned above, opioids and EBRT were permitted as
part of BSoC for bone pain management. Time to first use of
opioids for bone pain was assessed in patients not receiving
baseline opioids (ie, nonopioid subgroup). During the study,
opioids were required by 36% (96/269) of radium-223
patients versus 50% (70/139) of placebo patients who werenot receiving opioids at baseline. Radium-223 significantly
delayed time to first opioid use for bone pain versus placebo
(HR = 0.62, 95% CI: 0.46–0.85, p = 0.002; median not
estimable vs 6.9 mo, respectively; Fig. 2E).
During the study, 30% (186/614) of radium-223 patients
and34% (105/307)ofplacebopatients receivedEBRT forbone
pain. Radium-223 significantly reduced the risk of needing
EBRT for bone pain by 33% versus placebo (HR = 0.67, 95% CI:
0.53–0.85, p = 0.001; Supplementary Fig. 1). No differences
were seen in the safety profile between patientswho did and
did not receive concomitant EBRT for bone pain during the
study (Table 4). Additionally, myelosuppression rates were
low regardless of concomitant EBRT.
4. Discussion
In ALSYMPCA, patients were required to have symptomatic
disease to be eligible for the study; however, symptomatic
was broadly defined, in that opioid usewas not required and
patientswere defined asminimally symptomatic if they had
regular use of any analgesic medication or if they had
received EBRT in the 12 wk before randomization. This
opioid subgroup analysis was conducted to determine if the
radium-223 survival advantage in the overall ALSYMPCA
Table 2 – Efficacy endpoints (intent-to-treat population; N = 921)
Nonopioid subgroup Opioid subgroup
Radium-223
n = 269
Placebo
n = 139
Hazard ratioa
(95% CI)
p valueb Radium-223
n = 345
Placebo
n = 168
Hazard ratioa
(95% CI)
p valueb
Primary endpoint
Overall survival (mo)
Median (95% CI)
16.4 (14.4–18.4) 12.8 (11.3–16.0) 0.70 (0.52–0.93) 0.013 13.9 (11.9–15.4) 10.4 (8.7–11.6) 0.68 (0.54–0.86) 0.001
Main secondary efﬁcacy endpoints
Patients experiencing
an event, n (%)
Time to ﬁrst SSE (mo),
median (95% CI)
77 (29)
17.1 (14.7–NE)
50 (36)
19.5 (7.9–23.7)
0.56
(0.39–0.82)
0.002
125 (36)
12.9 (11.0–18.3)
66 (39)
7.9 (6.2–29.0)
0.72 (0.53–0.98) 0.038
Patients experiencing
an event, n (%)
Time to increase in tALP
level (mo), median
(95% CI)
44 (16)
7.4 (7.1–NE)
74 (53)
4.1 (3.6–4.3)
0.17
(0.11–0.25)
<0.001
62 (18)
NE
77 (46)
3.7 (3.5–4.1)
0.15
(0.11–0.22)
<0.001
Patients experiencing
an event, n (%)
Time to increase in PSA
level (mo), median
(95% CI)
168 (62)
3.6 (3.5–4.0)
94 (68)
3.5 (3.3–3.5)
0.68
(0.53–0.89)
0.004
220 (64)
3.6 (3.5–3.9)
99 (59)
3.4 (3.3–3.5)
0.62
(0.48–0.80)
<0.001
Patients with 30%
reduction in tALP
response, n (%)c 97/225 (43) 4/102 (4) NA <0.001d 136/272 (50) 3/109 (3) NA <0.001d
Patients with
normalization of
tALP level, n (%)e
51/131 (39) 0/65 (0) NA <0.001d 58/190 (31) 2/75 (3) NA <0.001d
CI = conﬁdence interval; NA = not applicable; NE = not estimable; PSA = prostate-speciﬁc antigen; radium-223 = radium-223 dichloride; SSE = symptomatic
skeletal event; tALP = total alkaline phosphatase.
a Hazard ratio (radium-223: placebo) is from a Cox proportional hazards model stratiﬁed by tALP, current use of bisphosphonates, and prior use of docetaxel.
b Unless otherwise noted, the p value is from the log-rank test stratiﬁed by tALP, current use of bisphosphonates, and prior use of docetaxel.
c n value is the number of patients with a conﬁrmed tALP response/the total number of patients with nonmissing tALP values. A 30% reduction was deﬁned
relative to the baseline value, and was conﬁrmed by a second tALP value approximately 4 or more wk later.
d p value is from a Cochran-Mantel-Haenszel test adjusted for the stratiﬁcation factors tALP, current use of bisphosphonates, and prior use of docetaxel.
e n value is the number of patients with an elevated baseline tALP that normalized on study/the total number of patients with an elevated baseline tALP.
Table 3 – Adverse events (AEs) by opioid subgroup (safety population; N = 901)
No. of patients
with an AE, n (%)
Nonopioid subgroup Opioid subgroup
Radium-223 n = 263 Placebo n = 138 Radium-223 n = 337 Placebo n = 163
All
grades
Grade 3 Grade 4 All
grades
Grade 3 Grade 4 All
grades
Grade 3 Grade 4 All
grades
Grade 3 Grade 4
Hematologic AEsa
Anemiab 69 (26) 26 (10) 4 (2) 38 (28) 14 (10) 0 118 (35) 39 (12) 7 (2) 54 (33) 23 (14) 2 (1)
Leukopenia 12 (5) 4 (2) 0 0 0 0 13 (4) 3 (1) 1 (<1) 1 (1) 1 (1) 0
Neutropenia 11 (4) 4 (2) 1 (<1) 1 (1) 1 (1) 0 19 (6) 5 (1) 3 (1) 2 (1) 1 (1) 0
Thrombocytopeniac 27 (10) 9 (3) 5 (2) 6 (4) 2 (1) 0 42 (12) 11 (3) 13 (4) 11 (7) 3 (2) 1 (1)
Nonhematologic AEsd
Constipation 46 (17) 2 (1) 0 26 (19) 0 0 62 (18) 4 (1) 0 38 (23) 4 (2) 0
Diarrhea 70 (27) 3 (1) 0 27 (20) 4 (3) 0 81 (24) 6 (2) 0 18 (11) 1 (1) 0
Nausea 79 (30) 4 (2) 0 39 (28) 2 (1) 0 134 (40) 6 (2) 0 65 (40) 3 (2) 0
Vomiting 42 (16) 5 (2) 0 15 (11) 3 (2) 0 69 (20) 5 (1) 0 26 (16) 4 (2) 0
Fatigue 63 (24) 5 (2) 2 (1) 33 (24) 7 (5) 1 (1) 91 (27) 16 (5) 1 (<1) 44 (27) 9 (6) 1 (1)
Peripheral edema 26 (10) 2 (1) 0 14 (10) 1 (1) 0 50 (15) 8 (2) 0 16 (10) 2 (1) 1 (1)
Weight decreased 25 (10) 3 (1) 0 19 (14) 1 (1) 0 44 (13) 1 (<1) 0 25 (15) 4 (2) 0
Anorexia 38 (14) 4 (2) 0 25 (18) 2 (1) 0 64 (19) 5 (1) 0 30 (18) 0 0
Bone pain 111 (42) 35 (13) 2 (1) 82 (59) 26 (19) 1 (1) 189 (56) 85 (25) 3 (1) 105 (64) 48 (29) 2 (1)
Malignant neoplasm
progressione
25 (10) 2 (1) 1 (<1) 13 (9) 2 (1) 0 52 (15) 7 (2) 3 (1) 31 (19) 2 (1) 1 (1)
radium-223 = radium-223 dichloride.
a All grades occurring in 5% of patients in either treatment subgroup.
b Grade 5 anemia occurred in one (1%) patient in the placebo group (nonopioid subgroup).
c Grade 5 thrombocytopenia occurred in one (<1%) patient in the radium-223 group (nonopioid subgroup); this was considered possibly drug related by the
investigator, and the patient died from pneumonia with no evidence of bleeding.
d All grades occurring in 15% of patients in either treatment subgroup.
e Grade 5 malignant neoplasm progression occurred in 17 (7%) patients in the radium-223 group and eight (6%) patients in the placebo group (nonopioid
subgroup) and in 38 (11%) patients in the radium-223 group and 25 (15%) patients in the placebo group (opioid subgroup).
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Table 4 – Adverse events (AEs) by concomitant external beam radiation therapy (EBRT) use (safety population; N = 901)
With concomitant EBRT Without concomitant EBRT
Radium-223 n = 227 Placebo n = 140 Radium-223 n = 373 Placebo n = 161
Patients with AEs, n (%) All grades Grades 3–4 All grades Grades 3–4 All grades Grades 3–4 All grades Grades 3–4
Hematologic AEs (all grades occurring in 5% of patients in either treatment subgroup)
Anemia 77 (34) 27 (12) 51 (36) 21 (15) 110 (29) 50 (13) 41 (25) 19 (12)
Leukopenia 7 (3) 2 (1) 0 (0) 0 (0) 18 (5) 6 (2) 1 (1) 1 (1)
Neutropenia 14 (6) 5 (2) 1 (1) 1 (1) 16 (4) 8 (2) 2 (1) 1 (1)
Thrombocytopenia 27 (12) 13 (6) 8 (6) 2 (1) 42 (11) 26 (7) 9 (6) 4 (2)
Nonhematologic AEs (all grades occurring in 15% of patients in either treatment subgroup)
Constipation 54 (24) 4 (2) 35 (25) 1 (1) 54 (14) 2 (1) 29 (18) 3 (2)
Diarrhea 71 (31) 1 (0) 26 (19) 3 (2) 80 (21) 8 (2) 19 (12) 2 (1)
Nausea 98 (43) 8 (4) 61 (44) 3 (2) 115 (31) 2 (1) 43 (27) 2 (1)
Vomiting 56 (25) 4 (2) 26 (19) 4 (3) 55 (15) 6 (2) 15 (9) 3 (2)
Fatigue 67 (30) 10 (4) 24 (17) 3 (2) 87 (23) 14 (4) 53 (33) 15 (9)
Weight decreased 33 (15) 2 (1) 20 (14) 2 (1) 36 (10) 2 (1) 24 (15) 3 (2)
Anorexia 31 (14) 2 (1) 30 (21) 0 (0) 71 (19) 7 (2) 25 (16) 2 (1)
Bone pain 158 (70) 80 (35) 103 (74) 48 (34) 142 (38) 45 (12) 84 (52) 29 (18)
Malignant neoplasm progression 31 (14) 14 (6) 17 (12) 9 (6) 46 (12) 22 (6) 27 (17) 14 (9)
radium-223 = radium-223 dichloride.
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level.
At study entry, 44% of radium-223 patients and 45% of
placebo patients were minimally symptomatic, with no pain
or mild pain and no opioid use; of these, 4% of radium-223
patients and1%ofplacebopatientswere completelypain free
at study entry. Radium-223 versus placebo significantly
prolonged OS, reduced risk of initial SSE, and improved
biochemical markers with a favorable safety profile in
ALSYMPCA patients, regardless of baseline opioid use. For
both radium-223 and placebo patients,minimally symptom-
atic patients (ie, WHO ladder pain score 0–1/without opioid
use) had longer OS than patients with more symptomatic
disease (ie, WHO ladder pain score 2–3/with opioid use).
Results from these opioid subgroup analyses showed that
radium-223 is effective and well tolerated in both minimally
symptomatic nonopioid patients (WHO ladder pain score
0–1) and those with more advanced symptomatic disease
who required opioid therapy (WHO ladder pain score 2–3),
suggesting that appropriate timing of radium-223 treatment
should not be based on symptom severity.
During ALSYMPCA, radium-223 treatment significantly
delayed time to first opioid use and reduced the risk of
needing EBRT for bone pain. Importantly, ALSYMPCA was
not designed to evaluate the effect of radium-223 on pain;
any observed pain response or lack thereof should not be
considered a reason to stop radium-223 treatment. In fact,
63% of ALSYMPCA patients in the radium-223 group were
able to receive all six injections of radium-223 [4], the
recommended course stated in approved radium-223
labeling. It is worth noting that concomitant EBRT had no
effect on AE incidence or severity; as part of BSoC, EBRTmay
be used as needed to manage pain in patients undergoing
radium-223 therapy. Using radium-223 earlier in the
disease course, when patients are minimally symptomatic,
may optimize treatment outcome and allow sequencing or
combination use with other life-prolonging therapies.
Additionally, radium-223 treatment has been shown toreduce hospitalization costs versus placebo [11]. Explorato-
ry analyses from an international expanded access program
with radium-223 (n = 696; included CRPC patients with
symptomatic or asymptomatic bone metastases) showed
that low or no pain at baseline was prognostic for prolonged
survival, and that radium-223 combined with abiraterone
acetate and/or enzalutamide was generally well tolerated
[12–14]. Randomized trials are ongoing to prospectively
evaluate radium-223 combined with abiraterone acetate
and enzalutamide in asymptomatic or mildly symptomatic
metastatic CRPC patients (NCT02043678; NCT02034552).
5. Conclusions
Radium-223 compared with placebo improved OS and
reduced the risk of initial SSE with a favorable safety profile
in patients with CRPC and symptomatic bone metastases,
regardless of baseline opioid use. These results show that
radium-223 is effective and well tolerated in both
minimally symptomatic nonopioid patients (WHO ladder
pain score 0–1) and patients with more advanced symp-
tomatic disease who required opioid therapy (WHO ladder
pain score 2–3) at baseline. This suggests that symptom
severity should not be the basis for determining appropriate
timing of radium-223 treatment.
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